These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 16755205)

  • 21. Pharmacological treatment of obesity.
    Mancini MC; Halpern A
    Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):377-89. PubMed ID: 16767304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treating obesity in the family practice setting.
    Fernstrom MH
    Postgrad Med; 2001 Jun; 109(6 Suppl):10-8. PubMed ID: 19667563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal treatments for the metabolic syndrome.
    Giugliano D; Esposito K
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):e30. PubMed ID: 16556857
    [No Abstract]   [Full Text] [Related]  

  • 24. Emerging concepts in the medical and surgical treatment of obesity.
    Aylwin S; Al-Zaman Y
    Front Horm Res; 2008; 36():229-259. PubMed ID: 18230906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel therapies for cardiometabolic risk reduction and implications for clinical practice.
    Watson KE
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S37-42. PubMed ID: 17934393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The new role of pharmacotherapy for weight reduction in obesity.
    Fernstrom MH; Fernstrom JD
    Int J Clin Pract; 2002 Nov; 56(9):683-6. PubMed ID: 12469983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Drug treatment of obesity].
    Svendsen OL; Toubro S; Breum L; Bruun JM; Astrup AV
    Ugeskr Laeger; 2006 Jan; 168(2):163-7. PubMed ID: 16403342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
    Van Gaal LF; Rissanen AM; Scheen AJ; Ziegler O; Rössner S;
    Lancet; 2005 Apr 16-22; 365(9468):1389-97. PubMed ID: 15836887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The endocannabinoid system as a target for obesity treatment.
    Aronne LJ; Pagotto U; Foster GD; Davis SN
    Clin Cornerstone; 2008; 9(1):52-64; discussion 65-6. PubMed ID: 19046740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug treatments for obesity: orlistat, sibutramine, and rimonabant.
    Padwal RS; Majumdar SR
    Lancet; 2007 Jan; 369(9555):71-7. PubMed ID: 17208644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Drug treatment of obesity].
    Burniat W
    Rev Med Brux; 2009; 30(2):124-6. PubMed ID: 19517912
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of sibutramine, orlistat and Ispaghula in reducing body weight and total body fat content in obese individuals.
    Kazmi SA; Khan M; Mashori GR; Saleem A; Akhtar N; Jahangeer A
    J Ayub Med Coll Abbottabad; 2009; 21(2):45-8. PubMed ID: 20524467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Association of obesity and depression].
    Rihmer Z; Purebl G; Faludi G; Halmy L
    Neuropsychopharmacol Hung; 2008 Oct; 10(4):183-9. PubMed ID: 19213197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unmet needs in controlling metabolic disease.
    Haffner SM
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S17-24. PubMed ID: 17934390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Positive influence on cardiovascular risk factor by blocking the endocannabinoid system].
    Chatterjee T; Ritz A; Ince H; Nienaber ChA; Rehders TC
    Praxis (Bern 1994); 2008 May; 97(11):613-21. PubMed ID: 18592956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.
    Després JP; Lemieux I; Bergeron J; Pibarot P; Mathieu P; Larose E; Rodés-Cabau J; Bertrand OF; Poirier P
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1039-49. PubMed ID: 18356555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacotherapy for obesity in menopausal women.
    Samat A; Rahim A; Barnett A
    Menopause Int; 2008 Jun; 14(2):57-62. PubMed ID: 18519266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.
    Sabuncu T; Nazligul Y; Karaoglanoglu M; Ucar E; Kilic FB
    Rom J Gastroenterol; 2003 Sep; 12(3):189-92. PubMed ID: 14502318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
    Wadden TA; Berkowitz RI; Womble LG; Sarwer DB; Arnold ME; Steinberg CM
    Obes Res; 2000 Sep; 8(6):431-7. PubMed ID: 11011909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.